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Abstract
Purpose To evaluate the proliferation rates of
five human uveal melanoma (UM) cell lines
after treatment with amfenac, a
cyclooxygenase (COX)-2 inhibitor, and
subsequent radiation exposure.
Methods Five human UM cell lines (92.1,
SP6.5, MKT-BR, OCM-1, and UW-1) and one
human fibroblast cell line (BJ) were incubated
with amfenac. Treated and non-treated cell
lines were then exposed to various doses of c
radiation: 0, 2, 4, 6, and 8 Gy. Sulphorhodamine-
B assay was used to assess proliferation rates
48 h post-radiation.
Results Treatment of UM cell lines with
amfenac prior to radiation led to a marked
reduction in proliferation rates. This difference
was statistically significant in all cell lines at
every radiation dose (Po0.005), with the
exception of 92.1 at 2 Gy (P¼ 0.157). Fibroblasts
treated with amfenac showed significantly
higher proliferation rates after 2 and 8 Gy, with
no significant differences at 0, 4, and 6 Gy.
Conclusions The radiosensitivity of UM cell
lines was increased by the administration of
amfenac, the active metabolite of nepafenac.
There appears to be a radioprotective effect of
amfenac on human fibroblasts. The topical
administration of nepafenac may decrease
tumour recurrence and radiation-induced
complications while broadening the indications
for radiotherapy by treating larger tumours.
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Introduction
Uveal melanoma (UM) is the most common
primary intraocular malignant tumour in adults
with an incidence of seven cases per million.1
Enucleation of the affected eye was the only
available treatment for UM for most of the last
century.2 However, with the advent of more
conservative alternatives to treat the primary
tumour, enucleation rates have substantially
declined in recent years. The procedure is now
reserved for large tumours or those cases where
there is no hope of regaining vision.3
Radiation is the preferred form of treatment
for most cases of UM.4 UMs are typically treated
with a calculated apex dose of 70–85 Gy.5
Iodine-125 is the most commonly used isotope
for plaque radiotherapy of choroidal
melanomas,6 although cobalt-60, ruthenium-
106, iridium-192, strontium-90, and palladium-
103 have also been used.3 Modern techniques
for brachytherapy involve suturing a shielded
plaque containing seeds of the radioactive
isotope to the sclera. This remains in place for a
specified number of days to deliver the proper
dose of radiation. Although the rates of tumour
control are high, visual acuity is compromised
in 25–35% of cases.6 Some of the complications
associated with the treatment are neovascular
glaucoma, cataract, radiation retinopathy, and
optic nerve neuropathy.7 Thus, a substantial
number of eyes are still enucleated due to
failure of tumour control or radiation-related
complications.
There are two forms of the cyclooxygenase
(COX) enzyme, COX-1 and COX-2. While COX-1
is expressed constitutively in normal tissues,8
COX-2 is an inducible enzyme expressed in
response to a variety of inflammatory and
mitogenic stimuli.9 COX-2 expression has been
reported in a wide variety of malignant
tumours,10–12 including uveal melanoma.13 The
expression of COX-2 has been linked to various
processes, including tumour proliferation,14
immunosuppression,15 and metastasis.16,17
Specific COX-2 inhibitors are currently in use
for patients diagnosed with familial
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adenomatous polyposis, a genetic disorder, which
predisposes patients to colon cancer.18 The effectiveness
of these selective inhibitors has been investigated in a
variety of tumours and shows promise for use as an
adjuvant therapy.19
COX-2 inhibitors have also previously been shown to
increase the radiosensitivity of lung20 and breast21 cancer
cell lines. Moreover, it has been demonstrated that a
COX-2 inhibitor is capable of minimizing radiation
damage to non-neoplastic tissues.22 Nepafenac is a COX-
2 inhibitor formulated for topical administration to the
eye.23,24 The purpose of our study was to determine the
effects of amfenac, the active metabolite of nepafenac, on
the radiosensitivity of five human UM cell lines and one
human fibroblast cell line.
Methods
Cell culture
Four previously characterized human UM cell lines (92.1,
SP6.5, MKT-BR, OCM-1), one transformed human uveal
melanocyte cell line (UW-1) and one human fibroblast
cell line (BJ, American Type Culture Collection, USA)
were incubated at 371C in a humidified 5% CO2-enriched
atmosphere.25 The cell lines used have previously been
graded in terms of proliferative and invasive abilities and
metastatic potential.25 The UM cell lines were cultured in
RPMI-1640 medium (Invitrogen, Burlington, ON,
Canada), supplemented with 5% heat inactivated fetal
bovine serum (FBS), 1% fungizone, and 1% penicillin–
streptomycin purchased from Invitrogen (Burlington,
ON, Canada). The fibroblast cell line was cultured in
DMEM medium (Invitrogen, Burlington, ON, Canada),
supplemented with 10% heat-inactivated FBS, 1%
fungizone, and 1% penicillin-streptomycin purchased
from Invitrogen (Burlington, ON, Canada). Cells were
cultured as a monolayer in 25 cm2 flasks (Fisher, Whitby,
ON, Canada) and observed two times weekly, at every
media change, for normal growth by phase contrast
microscopy. The cultures were grown to confluence and
passaged by treatment with 0.05% trypsin in EDTA
(Fisher) at 371C and washed in 7 ml RPMI-1640 media
before being centrifuged at 120 g for 10 min to form a
pellet. Cells were then suspended in 1 ml of medium and
counted using the Trypan Blue dye exclusion test for use
in all subsequent assays.
The UM cell lines 92.1, SP6.5, and MKT-BR were
established by Dr Jager (University Hospital Leiden, The
Netherlands), Dr Pelletier (Laval University, Quebec,
Canada) and Dr Belkhou (CJF INSERM, France),
respectively. Dr Albert (University of Wisconsin-
Madison, USA) established the OCM-1 and UW-1 cell
lines.26,27
Irradiation
Prior to radiation, each cell line was seeded at a
concentration of 500 000 cells per ml in micro petri dishes
and incubated overnight with a 150 nM concentration of
amfenac (Alcon Laboratories Inc., Fort Worth, TX, USA),
the active metabolite of nepafenac. The concentration of
150 nm was the recommended 50% inhibitory
concentration (IC50) of COX-2 activity.
28 On the following
day, the cells were exposed to graded doses of g
irradiation: 2, 4, 6, and 8 Gy (137Cs source, g Cell 1000).
Controls consisted of cell lines exposed to radiation
without prior incubation with amfenac.
Post radiation, all micro petri dishes containing
500 000 cells/plate were trypsinized using 0.05% Trypsin
in EDTA, then washed in 5% FBS RPMI solution, and
centrifuged for 5 min at 3000 g. The cells were then
diluted to a concentration of 50 000 cells/ml in 5% FBS
RPMI solution. These dilutions were seeded in a 96-well
plate format at a concentration of 5000 cells per well and
left to incubate at 371C for 48 h to adhere to the bottom of
the wells. After 48 h, we could already see colonies
formed. Thus, to guarantee exponential growth, we
chose to run the proliferation assay at this time point. The
proliferation assay was done in triplicate per exposure
condition.
Sulphorhodamine-B assay
The Sulphorhodamine-B assay kit (TOX-6, Sigma-Aldrich
Co., St Louis, Missouri, USA) was used to measure total
cell material as described previously.29 Each of the
treated and non-treated cell lines were seeded into wells
at a concentration of 5 103 cells per well, with a
minimum of three wells per cell line/radiation dose. The
cells were then allowed to incubate for 48 h at 371C.
Following the incubation period, the cells were fixed to
the bottom of the wells using a solution of 50%
Trichloroacetic acid for 1 h at 41C. The plates were then
rinsed with distilled water, to remove trichloroacetic acid
and medium, and later air dried. The Sulphorhodamine-
B dye solution was next added to each well and allowed
to stain for 25 min. The Sulphorhodamine-B solution was
subsequently removed by washing with a 10% acetic acid
solution and once more allowed to air dry. The dye that
had become incorporated into the fixed cells at the
bottom of the wells was solubilized in a 10 mM solution
of Tris. The absorbance of the solute was measured using
a microplate reader at a wavelength of 510 nm.
Data analysis
The Student’s t-test was used to compare proliferation
results between treated and non-treated cell lines after
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various doses of radiation. A value of Po0.05 was
considered statistically significant.
Results
The results of the Sulphorhodamine-B proliferation assay
for each cell line are presented in Figure 1. The actual
values, SD, and P-values are shown in Table 1. The effect
of radiation was significantly more pronounced in the
UM cell lines treated with amfenac. The difference in the
proliferation rates between treated and non-treated cell
lines was statistically significant in all cell lines at all
radiation doses (Po0.05), except for the 92.1 cell line
exposed to 2 Gy (P¼ 0.157).
The effect of amfenac on different doses of radiation is
seen in Figure 2. The proliferation rates of the treated cell
lines are represented as a percentage of the untreated
controls. A positive value means that the proliferation
rate was higher after the addition of the drug, thus
suggesting a radioprotective effect. In contrast, a negative
value means that the cell line proliferated less when the
compound was added, indicating that the effects of
radiation were enhanced. The effect of amfenac on the
radiosensitivity of all UM cell lines was more
pronounced with increasing doses of radiation. The
synergism between amfenac and radiation was more
pronounced in the MKT-BR, OCM-1, SP6.5, and UW-1
cell lines than in the 92.1 cell line.
A human fibroblast cell line was used to test the effect
of amfenac on the radiosensitivity of a non-neoplastic cell
type. The results of the Sulphorhodamine-B proliferation
assay did not show a statistically significant difference
for radiation doses of 4 and 6 Gy. Amfenac demonstrated
a radioprotective effect, in terms of statistically
significant higher proliferation rates, in the treated
fibroblasts after 2 and 8 Gy of radiation.
Discussion
There is increasing evidence that COX-2 inhibitors may
work as radiosensitizing agents.30 Systemic COX-2
inhibitors are being used in clinical trials for lung cancer
and the results are promising.20,31 To the best of our
knowledge, this is the first time that a drug has been
shown to increase the radiosensitivity of UM cell lines.
Furthermore, we demonstrated that no such synergistic
effect was seen in a non-neoplastic human fibroblast cell
line, that was, on the contrary, protected by the addition
of amfenac. The finding that the fibroblasts were actually
protected from the radiation damage provides in vitro
support to the findings of Liang et al.22 The authors
observed that mice treated with a COX-2 inhibitor
showed less damage to the surrounding tissues than the
control animals, after receiving 50 Gy of radiation.
Although it was proposed that the protective mechanism
would involve the reduction of cytokines and
chemokines, our in vitro results show that there is an
intrinsic effect not related to tissue inflammation or other
host-related factors.
Figure 1 Graphical representation of the effect of amfenac and radiation on cell lines. The absorbance level detected by the
Sulphorhodamine-B proliferation assay is seen on the y axis, while the doses of radiation are shown on the x axis. The solid and dashed
lines correspond to the non-treated and treated cell lines, respectively. A significant reduction on the proliferation rates was seen only
in the uveal melanoma cell lines.
Amfenac and uveal melanoma
BF Fernandes et al
703
Eye
UM is known to be a radioresistant tumour. In vitro
studies have shown that downstream defects in the p53
pathway may be involved in resistance to apoptosis,
even though the radioresistance of UM is unlikely to be
attributed to a single genetic defect.32 UM cell lines show
a wide range of radiosensitivity, which may be explained
by varied induction of apoptosis, and cell cycle
disruption.33 The mechanism underlying the synergistic
effect of COX-2 inhibitors and radiation remains elusive.
One of the proposed mechanisms is the accumulation of
cells in the G2S/M phase of the cell cycle, which is most
sensitive to ionizing radiation.34 Aside from the intrinsic
effect of COX-2 inhibition in cancer cells, the anti-
angiogenic properties of COX-2 inhibitors may further
facilitate induction of apoptosis in vivo and hinder
tumour growth.21
Nepafenac has a unique prodrug structure and
exhibits superior ocular bioavailability properties
compared to diclofenac, another NSAID available for
topical administration. Nepafenac is an inactive form
that requires intraocular bioactivation to become the
effective prostaglandin H synthase inhibitor, amfenac.35
Little hydrolytic conversion of nepafenac is seen during
transit. Following penetration, nepafenac diffuses
through the anterior and posterior chambers of the eye
and is accumulated and bioactivated in vascularized
tissues: iris, ciliary body, retina, and choroid.36 The end
result is a prolonged suppression of COX activity, which
is a distinct advantage over an NSAID with a free
carboxylic acid function. Nepafenac was the only topical
anti-inflammatory medication shown to inhibit the
blood–retinal barrier breakdown in an animal model of
ocular inflammation.24 Thus, it is believed that nepafenac
is the only topical NSAID to reach therapeutic levels in
the posterior segment of the eye. Concentration of the
drug achieves its highest peaks in ocular tissues 30 min
after topical administration.24
Complications secondary to treatment by plaque
radiotherapy occur in up to 70% of patients, especially
when treating larger tumours.7 Radiotherapy does not
affect only the neoplastic tissue in the eye.
Histopathological studies show increased necrosis,
inflammation, fibrosis, and tumour blood vessel damage
in irradiated eyes.37 The combination of COX-2 inhibitors
and radiation is a promising emerging therapy since
COX-2 inhibition can selectively enhance the
radiosensitivity of a tumour while allowing non-
neoplastic tissues to be spared.30 The concept that an eye-
drop, without significant side effects,38 can deliver the
drug to an intraocular UM is even more appealing since
the systemic complications related to COX-2 inhibition
can be circumvented.20
In light of our preliminary results, we would
encourage the use of nepafenac as an adjunct to
radiotherapy in the treatment of UM. However, further
studies are needed to characterize the exact mechanism
behind the observed synergism. Animal studies would
also be valuable before the institution of clinical trials in
humans.
In summary, we showed that the radiosensitivity of
UM cell lines could be increased by the administration of
amfenac, the active metabolite of a commercially
available anti-inflammatory topical eye medication. The
administration of such a drug to uveal melanoma
patients, before radiotherapy, may increase success rates
regarding local tumour treatment and control.
Table 1 Proliferation rates of five uveal melanoma and
fibroblast cell lines after radiation measured by the Sulpho-
rhodamine-B assay kit
Radiation
dose (Gy)
Without Amfenac
(absorbanceþ SD)
With Amfenac
(absorbanceþSD)
P-value
92.1
0 1.11±0.08 0.92±0.01 0.002
2 0.82±0.04 0.76±0.05 0.157
4 0.84±0.09 0.67±0.02 0.036
6 0.72±0.05 0.54±0.03 0.009
8 0.49± 0.07 0.3±0.01 0.007
MKT-BR
0 1.69 1.44 0.013
2 1.39 1.19 0.017
4 1.38 0.63 o0.001
6 0.8 0.33 o0.001
8 0.05 0.005 o0.001
OCM-1
0 1.42 1.26 0.017
2 1.15 0.69 o0.001
4 0.93 0.43 0.007
6 0.42 0.12 0.047
8 0.18 0.009 0.029
SP6.5
0 1.7 1.66 0.42
2 1.59 0.95 o0.001
4 0.86 0.31 o0.001
6 0.3 0.16 0.003
8 0.22 0.03 o0.001
UW-1
0 0.63 0.66 0.01
2 0.55 0.43 0.003
4 0.48 0.15 o0.001
6 0.43 0.04 o0.001
8 0.36 0.02 o0.001
Fibroblast (BJ)
0 0.46 0.48 0.555
2 0.31 0.47 o0.001
4 0.34 0.32 0.411
6 0.31 0.31 0.825
8 0.29 0.31 0.014
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